SCHEMBL2852592

SCHEMBL2852592

Clc1cc(Cl)c(-c2cc(Cl)ccc2Cl)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.57
HTR2B P41595 1/20 0.47
PDE4D Q08499 1/20 0.47
CNR2 P34972 1/20 0.44
TSHR P16473 5/20 0.44
ALDH1A1 P00352 5/20 0.44
CYP3A4 P08684 3/20 0.44
HSD17B10 Q99714 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
PTPN11 Q06124 1/20 0.44
IDO1 P14902 1/20 0.44
AHR P35869 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42
S100A4 P26447 1/20 0.42
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
PTPN1 P18031 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29489601 1.00 TP53 (0.57) TP53HTR2BPDE4DCNR2TSHR
SCHEMBL4445036 0.85 CNR2 (0.46) TP53HTR2BPDE4DCNR2TSHR
SCHEMBL440944 0.83 TP53 (0.61) TP53HTR2BPDE4DTSHRALDH1A1
SCHEMBL29364307 0.83 TP53 (0.61) TP53HTR2BPDE4DTSHRALDH1A1
SCHEMBL4445059 0.82 TP53 (0.48) TP53HTR2BPDE4DCNR2TSHR
SCHEMBL4459784 0.81 TP53 (0.42) TP53HTR2BPDE4DCNR2TSHR
SCHEMBL4452962 0.81 AHR (0.56) TP53TSHRALDH1A1CYP3A4HSD17B10
SCHEMBL4450570 0.80 TP53 (0.46) TP53HTR2BPDE4DCNR2TSHR
SCHEMBL4454535 0.80 TP53 (0.52) TP53HTR2BPDE4DCNR2TSHR
SCHEMBL29618916 0.80 TP53 (0.46) TP53HTR2BPDE4DCNR2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051430-A1 NEUTRALIZATION OF ACYL-COA BINDING PROTEIN CONFERS AUTOPHAGY-DEPENDENT ORGAN PROTECTION Institut National de la Santé et de la Recherche Médicale (FR) 2025-02-13 US claimed
EP-4475883-A1 NEUTRALIZATION OF ACYL-COA BINDING PROTEIN CONFERS AUTOPHAGY-DEPENDENT ORGAN PROTECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2024-12-18 EP claimed
WO-2023152637-A1 NEUTRALIZATION OF ACYL-COA BINDING PROTEIN CONFERS AUTOPHAGY-DEPENDENT ORGAN PROTECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2023-08-17 WO claimed
CN-111411051-B Lactobacillus helveticus and application thereof 江南大学 2022-04-22 CN claimed
CN-111073828-B Bifidobacterium longum subspecies longum and application thereof 江南大学 2022-04-15 CN claimed
EP-3881907-A1 METHOD FOR DECHLORINATION OF ONE OR MORE AROMATIC ORGANOCHLORINE COMPOUND(S) CONTAINED IN AN OIL OR FORMING SAID OIL - ASSOCIATED ELECTRICAL/ELECTRONIC DEVICE AND INSTALLATION Université de Lille (FR) 2021-09-22 EP claimed
EP-3752148-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING TEIXOBACTIN AND A PEGYLATED PHOSPHOLIPID, AND THEIR USE IN TREATING BACTERIAL INFECTION NOVOBIOTIC PHARMACEUTICALS LLC (US) 2026-05-27 EP disclosed
US-12622925-B2 Edible enterosorbents used to mitigate acute exposures to ingestible environmental toxins following outbreaks, natural disasters and emergencies NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2026-05-12 US disclosed
US-20260069588-A1 VEPDEGESTRANT FOR USE IN TREATING CANCER ARVINAS OPERATION INC (US) 2026-03-12 US disclosed
US-12545677-B2 Compounds useful as factor XIa inhibitors JANSSEN PHARMACEUTICA NV (BE) 2026-02-10 US disclosed
US-20250303213-A1 IN SITU TREATMENT SYSTEMS FOR REMEDIATION OF POLYCHLORINATED BIPHENYL CONTAMINATED BUILDING MATERIALS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2025-10-02 US disclosed
EP-4622951-A1 SELECTIVE BETA2-ADRENOCEPTOR ANTAGONIST Trio Medicines Limited (GB) 2025-10-01 EP disclosed
EP-4185587-B1 COMPOUNDS USEFUL AS FACTOR XIA INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2025-09-10 EP disclosed
US-20170114187-A9 GELS AORTECH INTERNATIONAL PLC (GB) 2017-04-27 US disclosed
US-20140323676-A1 GELS AORTECH INTERNATIONAL PLC (GB) 2014-10-30 US disclosed
US-8623986-B2 Gels Aertech International plc (GB) 2014-01-07 US disclosed
US-20100029802-A1 Gels AORTECH INTERNATIONAL PLC (GB) 2010-02-04 US disclosed
US-20090269857-A1 Instruments for detecting low-molecular weight substance FUJIKURA KASEI CO., LTD. (JP) 2009-10-29 US disclosed
US-20050148097-A1 Instruments for detecting low-molecular weight substance ENBIOTEC LABORATORIES C., LTD. (JP) 2005-07-07 US disclosed
EP-1489420-A1 INSTRUMENTS FOR DETECTING LOW-MOLECULAR WEIGHT SUBSTANCE Enbiotec Laboratories Co., Ltd. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622925-B2 Edible enterosorbents used to mitigate acute exposures to ingestible environmental toxins following outbreaks, natural disasters and emergencies FABP2, LCT, DDT TP53 380/4885HTR2B 1151/4885PDE4D 4073/4885
US-12545677-B2 Compounds useful as factor XIa inhibitors F2, F11, F10 TP53 4071/4885HTR2B 2642/4885PDE4D 3777/4885
US-20260069588-A1 VEPDEGESTRANT FOR USE IN TREATING CANCER PSMC1, PSMC5, PSME3 TP53 163/4885HTR2B 2991/4885PDE4D 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.